Layoffs at Life Science, Dx Firms Continue as Thermo Fisher Scientific, Natera Shrink Payrolls
In 2023, Thermo Fisher has laid off nearly 400 California employees at sites associated with Mesa Biotech, acquired in 2021 for $450 million in cash.
MolDx Reimbursement Decision Likely to Have Negative Impact on CareDx, Natera Transplant Businesses
MolDx updated its guidance for rejection risk molecular testing with more restrictive language, potentially ending multimodal test coverage.
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.
Natera Q4, Full-Year Revenues Rise on Increased Product Sales, Test Volume
Test volumes rose by nearly 28 percent year over year to approximately 559,700 tests in Q4 2022.
People in the News at Natera, Delfi Diagnostics, Biocartis, Ansa Bio, Lex Diagnostics, More
Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of Feb. 20, 2023.
Nov 9, 2022
Oct 20, 2022